Borja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.
Borja Puertas‐Martinez, MD
Advertisement
Articles by Borja Puertas‐Martinez, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
2
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
3
First-Line Zanubrutinib Is Associated With Improved Real-World Efficacy in Older Patients With CLL
4
FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer
5